Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Neuropsychobiology
|
January 1, 1979
Effect of benztropine on haloperidol-induced prolactin secretion
S Lal, T Mendis, P Cervantes, et al.
Clinical Neuropharmacology
|
February 1, 1995
Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease
E Mohr, V Knott, M Sampson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 18, 2008
Impact of standard of care for psychosis in Parkinson disease
T R Thomsen, M Panisset, O Suchowersky, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 1994
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride
T Mendis, E Mohr, A George, et al.
Neurology
|
June 4, 2008
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M Stacy, D Silver, T Mendis, et al.
Clinical Neuropharmacology
|
August 1, 1997
Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates
E Mohr, N P Nair, M Sampson, et al.
Lancet (London, England)
|
March 4, 1978
Clinical effects of choline in Alzheimer's disease
P Etienne, S Gauthier, G Johnson, et al.
Journal of Medicinal Chemistry
|
May 13, 2015
New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase
Wei Li, Suqing Zheng, Maureen Higgins, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Neuropsychobiology
|
January 1, 1979
Effect of benztropine on haloperidol-induced prolactin secretion
S Lal, T Mendis, P Cervantes, et al.
Clinical Neuropharmacology
|
February 1, 1995
Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease
E Mohr, V Knott, M Sampson, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 18, 2008
Impact of standard of care for psychosis in Parkinson disease
T R Thomsen, M Panisset, O Suchowersky, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
March 1, 1994
Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride
T Mendis, E Mohr, A George, et al.
Neurology
|
June 4, 2008
A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease
M Stacy, D Silver, T Mendis, et al.
Clinical Neuropharmacology
|
August 1, 1997
Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates
E Mohr, N P Nair, M Sampson, et al.
Lancet (London, England)
|
March 4, 1978
Clinical effects of choline in Alzheimer's disease
P Etienne, S Gauthier, G Johnson, et al.
Journal of Medicinal Chemistry
|
May 13, 2015
New Monocyclic, Bicyclic, and Tricyclic Ethynylcyanodienones as Activators of the Keap1/Nrf2/ARE Pathway and Inhibitors of Inducible Nitric Oxide Synthase
Wei Li, Suqing Zheng, Maureen Higgins, et al.
Page
of 2